The hypertriglyceridemia drugs market size has grown strongly in recent years. It will grow from $7.06 billion in 2025 to $7.58 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing burden of cardiovascular diseases, higher intake of high-fat dietary patterns, improved awareness of lipid-related disorders, wider use of statins and fibrates, and enhanced availability of lipid profiling diagnostic tools.
The hypertriglyceridemia drugs market size is expected to see strong growth in the next few years. It will grow to $10.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing use of precision lipid-lowering treatment approaches, development of innovative biologic therapies targeting lipid disorders, expansion of personalized medicine strategies, rising number of clinical studies focused on triglyceride-modifying agents, and increased healthcare spending on preventive cardiometabolic interventions. Key trends during this period include the adoption of apolipoprotein C-III inhibition therapies for severe triglyceride reduction, growing use of angiopoietin-like protein 3 (ANGPTL3) targeted lipid-lowering agents, development of microsomal triglyceride transfer protein inhibitors for resistant hypertriglyceridemia cases, emergence of RNA interference-based lipid regulation treatments, and wider application of combination therapies involving fibrates, omega-3 fatty acids, and statins.
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the hypertriglyceridemia drugs market. Cardiovascular diseases (CVDs) refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, stroke, heart failure, and hypertension. The rising prevalence of cardiovascular diseases is primarily driven by unhealthy lifestyles, which adversely impact heart health and elevate the risk of developing heart-related disorders. Hypertriglyceridemia drugs support the management of cardiovascular diseases by reducing excessively high triglyceride levels in the blood, thereby lowering plaque buildup in arteries and decreasing the risk of heart attacks and strokes. For instance, in March 2025, according to the Joint Strategic Needs Assessment, a UK-based community health center, the number of deaths caused by cardiovascular disease (CVD) was 185 in 2023, compared to 178 recorded in 2022. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the hypertriglyceridemia drugs market.
Key companies operating in the hypertriglyceridemia drugs market are focusing on developing innovative therapies, such as ribonucleic acid interference (RNAi)-based triglyceride-lowering drugs to reduce triglyceride levels, improve cardiovascular outcomes, and address severe lipid disorders more effectively. RNAi-based triglyceride-lowering drugs are advanced therapies that use small interfering RNA molecules to selectively silence genes involved in triglyceride production and metabolism, helping reduce circulating triglyceride levels more precisely and for longer durations compared to conventional lipid-lowering medications that often require frequent dosing and may have broader systemic effects. for example, in December 2025, Arrowhead Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for FDA Breakthrough Therapy Designation for Plozasiran, an investigational RNAi therapeutic for severe hypertriglyceridemia. The therapy is designed to reduce the production of apolipoprotein C-III (APOC3), a key regulator of triglyceride metabolism associated with elevated triglyceride levels and pancreatitis risk. Plozasiran demonstrated significant triglyceride-lowering effects in clinical studies and is intended to provide sustained efficacy with infrequent dosing schedules, improving treatment adherence and long-term lipid management. The designation highlights its potential to address unmet clinical needs among patients with severe hypertriglyceridemia who are at high risk of cardiovascular complications and acute pancreatitis.
In October 2025, F. Hoffmann-La Roche Ltd., a Switzerland-based biotechnology company, completed the acquisition of 89bio Inc. for $3.5 billion. Through this deal, Roche intends to enhance its cardiovascular, renal, and metabolic disease portfolio by incorporating 89bio’s late-stage FGF21 analog therapy for metabolic dysfunction-associated steatohepatitis (MASH), while also broadening its footprint in obesity-related and liver disease therapeutics. 89bio Inc. is a US-based company focused on developing treatments for severe hypertriglyceridemia (SHTG), a condition characterized by extremely high triglyceride concentrations.
Major companies operating in the hypertriglyceridemia drugs market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, AbbVie Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Viatris Inc., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Shionogi & Co. Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Cipla Limited, Zydus Lifesciences Limited, Kowa Company Ltd., Amarin Corporation plc, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., 89bio Inc., Arrowhead Pharmaceuticals Inc., NorthSea Therapeutics B.V., Staten Biotechnology B.V.
North America was the dominant region in the hypertriglyceridemia drugs market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in hypertriglyceridemia drugs report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypertriglyceridemia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hypertriglyceridemia drugs market consists of sales of antisense oligonucleotides, peroxisome proliferator-activated receptor (PPAR) agonists, and triglyceride-lowering injectable biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The hypertriglyceridemia drugs market research report is one of a series of new reports that provides hypertriglyceridemia drugs market statistics, including hypertriglyceridemia drugs industry global market size, regional shares, competitors with a hypertriglyceridemia drugs market share, detailed hypertriglyceridemia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hypertriglyceridemia drugs industry. This hypertriglyceridemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The hypertriglyceridemia drugs market size is expected to see strong growth in the next few years. It will grow to $10.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing use of precision lipid-lowering treatment approaches, development of innovative biologic therapies targeting lipid disorders, expansion of personalized medicine strategies, rising number of clinical studies focused on triglyceride-modifying agents, and increased healthcare spending on preventive cardiometabolic interventions. Key trends during this period include the adoption of apolipoprotein C-III inhibition therapies for severe triglyceride reduction, growing use of angiopoietin-like protein 3 (ANGPTL3) targeted lipid-lowering agents, development of microsomal triglyceride transfer protein inhibitors for resistant hypertriglyceridemia cases, emergence of RNA interference-based lipid regulation treatments, and wider application of combination therapies involving fibrates, omega-3 fatty acids, and statins.
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the hypertriglyceridemia drugs market. Cardiovascular diseases (CVDs) refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, stroke, heart failure, and hypertension. The rising prevalence of cardiovascular diseases is primarily driven by unhealthy lifestyles, which adversely impact heart health and elevate the risk of developing heart-related disorders. Hypertriglyceridemia drugs support the management of cardiovascular diseases by reducing excessively high triglyceride levels in the blood, thereby lowering plaque buildup in arteries and decreasing the risk of heart attacks and strokes. For instance, in March 2025, according to the Joint Strategic Needs Assessment, a UK-based community health center, the number of deaths caused by cardiovascular disease (CVD) was 185 in 2023, compared to 178 recorded in 2022. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the hypertriglyceridemia drugs market.
Key companies operating in the hypertriglyceridemia drugs market are focusing on developing innovative therapies, such as ribonucleic acid interference (RNAi)-based triglyceride-lowering drugs to reduce triglyceride levels, improve cardiovascular outcomes, and address severe lipid disorders more effectively. RNAi-based triglyceride-lowering drugs are advanced therapies that use small interfering RNA molecules to selectively silence genes involved in triglyceride production and metabolism, helping reduce circulating triglyceride levels more precisely and for longer durations compared to conventional lipid-lowering medications that often require frequent dosing and may have broader systemic effects. for example, in December 2025, Arrowhead Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for FDA Breakthrough Therapy Designation for Plozasiran, an investigational RNAi therapeutic for severe hypertriglyceridemia. The therapy is designed to reduce the production of apolipoprotein C-III (APOC3), a key regulator of triglyceride metabolism associated with elevated triglyceride levels and pancreatitis risk. Plozasiran demonstrated significant triglyceride-lowering effects in clinical studies and is intended to provide sustained efficacy with infrequent dosing schedules, improving treatment adherence and long-term lipid management. The designation highlights its potential to address unmet clinical needs among patients with severe hypertriglyceridemia who are at high risk of cardiovascular complications and acute pancreatitis.
In October 2025, F. Hoffmann-La Roche Ltd., a Switzerland-based biotechnology company, completed the acquisition of 89bio Inc. for $3.5 billion. Through this deal, Roche intends to enhance its cardiovascular, renal, and metabolic disease portfolio by incorporating 89bio’s late-stage FGF21 analog therapy for metabolic dysfunction-associated steatohepatitis (MASH), while also broadening its footprint in obesity-related and liver disease therapeutics. 89bio Inc. is a US-based company focused on developing treatments for severe hypertriglyceridemia (SHTG), a condition characterized by extremely high triglyceride concentrations.
Major companies operating in the hypertriglyceridemia drugs market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, AbbVie Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Viatris Inc., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Shionogi & Co. Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Cipla Limited, Zydus Lifesciences Limited, Kowa Company Ltd., Amarin Corporation plc, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., 89bio Inc., Arrowhead Pharmaceuticals Inc., NorthSea Therapeutics B.V., Staten Biotechnology B.V.
North America was the dominant region in the hypertriglyceridemia drugs market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in hypertriglyceridemia drugs report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypertriglyceridemia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hypertriglyceridemia drugs market consists of sales of antisense oligonucleotides, peroxisome proliferator-activated receptor (PPAR) agonists, and triglyceride-lowering injectable biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The hypertriglyceridemia drugs market research report is one of a series of new reports that provides hypertriglyceridemia drugs market statistics, including hypertriglyceridemia drugs industry global market size, regional shares, competitors with a hypertriglyceridemia drugs market share, detailed hypertriglyceridemia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hypertriglyceridemia drugs industry. This hypertriglyceridemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hypertriglyceridemia Drugs Market Characteristics
3. Hypertriglyceridemia Drugs Market Supply Chain Analysis
4. Global Hypertriglyceridemia Drugs Market Trends And Strategies
5. Hypertriglyceridemia Drugs Market Analysis Of End Use Industries
7. Global Hypertriglyceridemia Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Hypertriglyceridemia Drugs Total Addressable Market (TAM) Analysis for the Market
9. Hypertriglyceridemia Drugs Market Segmentation
10. Hypertriglyceridemia Drugs Market Regional And Country Analysis
11. Asia-Pacific Hypertriglyceridemia Drugs Market
12. China Hypertriglyceridemia Drugs Market
13. India Hypertriglyceridemia Drugs Market
14. Japan Hypertriglyceridemia Drugs Market
15. Australia Hypertriglyceridemia Drugs Market
16. Indonesia Hypertriglyceridemia Drugs Market
17. South Korea Hypertriglyceridemia Drugs Market
18. Taiwan Hypertriglyceridemia Drugs Market
19. South East Asia Hypertriglyceridemia Drugs Market
20. Western Europe Hypertriglyceridemia Drugs Market
21. UK Hypertriglyceridemia Drugs Market
22. Germany Hypertriglyceridemia Drugs Market
23. France Hypertriglyceridemia Drugs Market
24. Italy Hypertriglyceridemia Drugs Market
25. Spain Hypertriglyceridemia Drugs Market
26. Eastern Europe Hypertriglyceridemia Drugs Market
27. Russia Hypertriglyceridemia Drugs Market
28. North America Hypertriglyceridemia Drugs Market
29. USA Hypertriglyceridemia Drugs Market
30. Canada Hypertriglyceridemia Drugs Market
31. South America Hypertriglyceridemia Drugs Market
32. Brazil Hypertriglyceridemia Drugs Market
33. Middle East Hypertriglyceridemia Drugs Market
34. Africa Hypertriglyceridemia Drugs Market
36. Hypertriglyceridemia Drugs Market Competitive Landscape And Company Profiles
37. Hypertriglyceridemia Drugs Market Other Major And Innovative Companies
41. Hypertriglyceridemia Drugs Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Hypertriglyceridemia Drugs Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hypertriglyceridemia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hypertriglyceridemia drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hypertriglyceridemia drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Classes: Statins; Fibrates; Omega Three Fatty Acid Derivatives; Niacin; Combination Drugs; Other Drug Classes2) By Disease Type: Primary Hypertriglyceridemia; Secondary Hypertriglyceridemia
3) By Route Of Administration: Oral; Injectable
4) By End Use: Hospitals; Specialty Clinics; Ambulatory Care Centers
Subsegments:
1) By Statins: Atorvastatin; Rosuvastatin; Simvastatin; Pravastatin2) By Fibrates: Fenofibrate; Gemfibrozil; Bezafibrate; Ciprofibrate
3) By Omega Three Fatty Acid Derivatives: Icosapent Ethyl; Omega Three Acid Ethyl Esters; Omega Three Carboxylic Acids; Eicosapentaenoic Acid Derivatives
4) By Niacin: Immediate Release Niacin; Extended Release Niacin; Sustained Release Niacin; Combination Niacin Formulations
5) By Combination Drugs: Statin And Fibrate Combinations; Statin And Omega Three Fatty Acid Combinations; Statin And Niacin Combinations; Multi Component Lipid Lowering Combinations
6) By Other Drug Classes: Apolipoprotein C Three Inhibitors; Angiopoietin Like Protein Three Inhibitors; Ribonucleic Acid Interference Therapies; Microsomal Triglyceride Transfer Protein Inhibitors
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Sanofi S.A.; AstraZeneca plc; AbbVie Inc.; Novo Nordisk A/S; Teva Pharmaceutical Industries Ltd.; Viatris Inc.; Regeneron Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Shionogi & Co. Ltd.; Dr. Reddy’s Laboratories Ltd.; Lupin Limited; Cipla Limited; Zydus Lifesciences Limited; Kowa Company Ltd.; Amarin Corporation plc; Ionis Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.; 89bio Inc.; Arrowhead Pharmaceuticals Inc.; NorthSea Therapeutics B.V.; Staten Biotechnology B.V.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Pfizer Inc.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A.
- AstraZeneca plc
- AbbVie Inc.
- Novo Nordisk A/S
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Regeneron Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
- Shionogi & Co. Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Lupin Limited
- Cipla Limited
- Zydus Lifesciences Limited
- Kowa Company Ltd.
- Amarin Corporation plc
- Ionis Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- 89bio Inc.
- Arrowhead Pharmaceuticals Inc.
- NorthSea Therapeutics B.V.
- Staten Biotechnology B.V.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | April 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.58 Billion |
| Forecasted Market Value ( USD | $ 10.15 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
